Janssen Pharmaceutica NV had disclosed new pyrrolidinone derivatives acting as NF-κB-inducing kinase (NIK; MAP3K14) inhibitors and reported to be useful for the treatment of cancer.

Kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer have been detailed in a recent GT Apeiron Therapeutics patent.

Research at Nanjing Gritpharma Co. Ltd. has led to the identification of stilbene derivatives acting as aryl hydrocarbon receptor (AhR) agonists. As such, they are reported to be useful for the treatment of allergy, asthma, atherosclerosis, diabetes type 2, infections, osteoporosis, transplant rejection and graft-vs.-host disease.

Radionetics Oncology Inc. has patented new melanocortin MC2 receptor ligands reported to be useful for the diagnosis and treatment of cancer.

Biotheryx Inc. has developed new proteolysis targeting chimeras (PROTACs) comprising a E3 ubiquitin ligase binding moiety covalently bonded to a CDK protein-targeting moiety through a linker.

Voronoi and Voronoi Bio Inc. have patented heteroaryl derivative compounds acting as serine/threonine-protein kinase B-raf (BRAF) inhibitors and reported to be useful for the treatment of cancer.

Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors are described in a Relay Therapeutics Inc. patent as potentially useful for the treatment of cancer, particularly, breast and ovarian cancer.

Merck Sharp & Dohme LLC has patented compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.

A Genentech Inc. patent discloses new benzothiazole compounds acting as von Hippel-Lindau disease tumor suppressor (VHL) inhibitors and reported to be useful for the treatment of ischemia, cancer and anemia.

Research at Prelude Therapeutics Inc. has led to the development of SMARCA2 and/or SMARCA4 degradation inducers.